Introduction {#s1}
============

Retinal dystrophies are to date the most genetically heterogeneous set of inherited conditions known to affect a single organ. This complicates genetic screening for conditions such as retinitis pigmentosa (RP), cone-rod dystrophy (CRD) and Leber congenital Amaurosis (LCA) since each can result from mutations in many genes (see RetNet, <https://sph.uth.tmc.edu/retnet/>) which, with the exception of LCA, follow dominant, recessive or X-linked patterns of inheritance. Nationally, inherited retinal disease accounts for 4.2% of all sight impairment certifications and 5.5% of blindness cases [@pone.0104281-Bunce1]. These diseases are a more significant issue in the West Yorkshire population due to the high incidence of first cousin marriage and consequent recessive disease in the local Pakistani community [@pone.0104281-Darr1]. Until recently, patients could at best be offered only limited counselling based on approximate recurrence rates for a given mode of inheritance, whilst presymptomatic diagnosis and carrier status testing were impossible in all but a minority of cases. A further incentive for seeking to improve this situation is the notable success of an increasing number of clinical trials for gene and other targeted therapies for retinal dystrophies [@pone.0104281-Bainbridge1]--[@pone.0104281-Han1]. These are gene-specific, meaning that only patients for whom mutations have been identified will benefit from these novel approaches to stratified medicine.

In order to increase patient recruitment to new gene- or mutation-specific trials, several groups have already highlighted the potential of next generation sequencing in disease diagnosis [@pone.0104281-Bowne1]--[@pone.0104281-Shanks1]. Here we confirm the efficacy of this approach in a Northern UK cohort. In addition we describe the use of a previously published approach, tagging and DNA pooling prior to targeted capture and next generation sequencing [@pone.0104281-Harakalova1], providing a valuable refinement to existing high throughput next generation sequencing strategies for identifying the genetic basis of retinal dystrophy.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

Patients and their relatives recruited to the study gave informed, written consent using a process approved by the Leeds East Research Ethics committee (Project number 03/362), adhering to the tenets of the Declaration of Helsinki.

Samples {#s2b}
-------

The families were selected on the basis that there were multiple affected members with an unidentified molecular genetic diagnosis. The patients were diagnosed with a retinal dystrophy by an experienced ophthalmologist. Pedigree structures are depicted in [Figure 1](#pone-0104281-g001){ref-type="fig"}, while diagnoses, possible inheritance patterns, ethnicity and summary information regarding numbers of affected cases and members who were available for sampling are recorded in Table S1 in [File S1](#pone.0104281.s001){ref-type="supplementary-material"}. Peripheral blood was collected from affected patients, their parents and unaffected relatives where available. Genomic DNA was extracted from blood according to standard procedures.

![Family pedigrees of patients that were studied.\
Individuals from whom DNA was available are assigned the DNA notation in small lettering to the top right hand side of the symbol (and are also numbered). \* highlights pedigrees that have been abbreviated for this figure.](pone.0104281.g001){#pone-0104281-g001}

Target design {#s2c}
-------------

In order to enrich specific regions of the patient\'s genomic DNA, a liquid-phase reagent comprising 'SureSelect Target Enrichment' biotinylated cRNA baits was designed using the Agilent Technologies eArray software (<http://www.genomics.agilent.com/>) (Agilent Technologies UK Limited, Wokingham, UK). In total, 2,988 coding exons as well as a single intronic region, and their 100 bp flanking sequences, were selected in the UCSC genome database (<http://www.genome.ucsc.edu/>) from all of the 162 genes implicated in retinal degeneration (RetNet, July 2010). The list of genes targeted is shown in Table S2 in [File S1](#pone.0104281.s001){ref-type="supplementary-material"}. This consisted of 46,287 RNA baits at 5× tiling to cover 776.5 kb of DNA sequence. Probes could not be designed against 9 exons (Table S3 in [File S1](#pone.0104281.s001){ref-type="supplementary-material"}).

Library construction and massively parallel sequencing {#s2d}
------------------------------------------------------

Genomic DNA was sheared using a Covaris S220 sonicator. Illumina sequencing adapters containing 6 bp sequence tags were ligated to the samples, with each DNA sample being ligated to a different tag. The tagged DNA libraries were pooled into batches and captured using the SureSelect custom baits according to the manufacturer\'s instructions. Each captured pool was sequenced using single-end 80 bp reads on an Illumina GAIIx Sequencer (Illumina Inc., Little Chesterford, UK) according to the manufacturer\'s instructions.

Alignments and variant detection {#s2e}
--------------------------------

Sequence data were generated in qseq format and barcode sorted by their unique 5′ tag using NovoSort. The sorted fastq files have been deposited in the European Nucleotide Archive (<http://www.ebi.ac.uk/ena/>) with study accession number, PRJEB6380. The reads were aligned to the human genome sequence, hg19, using Novoalign (v2.08.01). Following realignment around indels, the GATK (v2.0.34) Unified Genotyper was used to identify variants [@pone.0104281-DePristo1]. The output VCF files were annotated for analysis using Alamut-HT (v1.0.4) (Interactive Biosoftware, Rouen, France). Analysis of read depth was performed using BEDTools (v2.15.0) and the GATK Count Reads walker.

Variants were filtered to exclude those more than 5 bp beyond the splice site junction. Synonymous variants and those with minor allele frequencies ≥0.01 in dbSNP or the 1,000 genomes project were also excluded.

From the remaining list, variants were then selected for further analysis if they met one or both of the following criteria. Firstly, variants that occurred in genes that had previously been associated with the observed phenotype and showed the expected pattern of inheritance were selected. Secondly, null alleles resulting from nucleotide deletions or insertions, premature stop codon mutations or changes affecting the conserved 2 bp adjacent to the splice site junction as well as missense variants with at least 2 out of 4 high pathogenicity scores were selected. For a high pathogenicity profile, scores recorded in the Alamut-HT report included BLOSUM62 ([Blo]{.ul}cks [Su]{.ul}bstitution [M]{.ul}atrix; <http://www.uky.edu/Classes/BIO/520/BIO520WWW/blosum62.htm>) \<0, AGVGD ([A]{.ul}lign [G]{.ul}rantham [V]{.ul}ariation and [G]{.ul}rantham [D]{.ul}eviation; <http://agvgd.iarc.fr/agvgd_input.php>) between C15 and C65, SIFT ([S]{.ul}orts [I]{.ul}ntolerant [F]{.ul}rom [T]{.ul}olerant substitutions, <http://sift.jcvi.org>) \<0.05 or deleterious and MAPP ([M]{.ul}ultivariate [A]{.ul}nalysis of [P]{.ul}rotein [P]{.ul}olymorphism; <http://mendel.stanford.edu/SidowLab/downloads/MAPP>) = bad. A schematic for the sequencing and informatics pipeline is shown in [Figure 2](#pone-0104281-g002){ref-type="fig"}. For any cases with a diagnosis of LCA, the unfiltered variant lists were also analysed for the deep intronic mutation c.2991+1655A\>G in *CEP290* that causes this phenotype [@pone.0104281-denHollander1].

![Schematic for next generation sequencing and variant detection.\
The strategy for NGS library preparation (A) and informatics used (B) are depicted.](pone.0104281.g002){#pone-0104281-g002}

Sanger sequencing of potential disease-causing variants {#s2f}
-------------------------------------------------------

Variants selected by the above criteria were confirmed by conventional Sanger sequencing of patient genomic DNA using the BigDye terminator cycle sequencing kit (Applied Biosystems, Paisley, UK) on an ABI3130xl sequencer (Applied Biosystems) and analysed using Sequencing Analysis v.5.2 software (Applied Biosystems). This was used to confirm presence of the mutation and test whether the mutation segregated with the disease phenotype in the family in question.

Confirmed pathogenic mutations were deposited in the publicly available LOVD database (<http://databases.lovd.nl/shared/>).

Results {#s3}
=======

Validating the capture reagent and establishing a pipeline for variant detection {#s3a}
--------------------------------------------------------------------------------

To test the feasibility of identifying pathogenic mutations in genomic DNA from patients with retinal degeneration, we selected four patients in whom, by Sanger sequencing of candidate genes, we had identified mutation(s) deemed clearly causative based on exclusion from control cohorts, predicted pathogenicity and segregation in additional family members. The analysis of the data for this study was conducted by one of the co-authors (David A Parry) without prior knowledge of these known mutations in the samples. Briefly, a sequencing adapter containing a different 6 bp sequence tag was ligated to each patient\'s sonicated DNA. The tagged aliquots were pooled prior to hybridisation against the target enrichment reagent and run on a single lane of the Illumina GAIIx DNA sequencer. The sequence data for each sample was sorted by sequence tag and aligned against the human reference sequence for analysis of coverage and read depth ([Table 1](#pone-0104281-t001){ref-type="table"}). Pooling of 4 samples gave a range of coverage between 95.6% to 96.9% with at least 20 good quality reads following duplicate removal and between 1 and 2% that had less than 5× read depth. A list of variants was generated for each sample and these were filtered without family history information according to the criteria highlighted in [Table 2](#pone-0104281-t002){ref-type="table"}, and described in the Methods section, to give rise to a list of candidate variants for each sample (Table S4 in [File S1](#pone.0104281.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0104281.t001

###### Coverage and read depth following targeted capture and next generation sequencing for the 4 patient verification study.

![](pone.0104281.t001){#pone-0104281-t001-1}

  Sample                         Tag     Aligned Reads   Reads on target   \% Reads on target   Mean coverage   \% ≥5   \% ≥10   \% ≥15   \% ≥20\*   \% ≥30   \% ≥50
  ---------------------------- -------- --------------- ----------------- -------------------- --------------- ------- -------- -------- ---------- -------- --------
  Patient A tag1                CAACCT     6,296,720        1,310,107            20.8%               133        98.5     97.7     96.8      95.7      93.3     86.5
  Patient B tag2                AACCAT     5,788,340        1,359,182            23.5%               137        98.4     97.5     96.6      95.6      93.4     87.9
  Patient C tag3                AAGGAT     8,539,613        2,174,816            25.5%               220        98.7     98.2     97.6      96.9      95.9     93.1
  Patient D tag4                AATTAT     4,314,207        1,609,443            37.3%               164        98.5     97.6     96.7      95.8      93.9     88.8
  Patient tag1 to 4, AVERAGE     98.5        97.8             96.9                96.0              94.1        89.1                                         

The tagging, aligned reads, reads on target, % reads on target, mean coverage and % coverage with a particular minimum read depth are shown for each patient DNA. The asterix highlights the % coverage with a greater than or equal to 20 read depth.

10.1371/journal.pone.0104281.t002

###### Filtering the variant lists following targeted capture and next generation sequencing for the 4 patient verification study.

![](pone.0104281.t002){#pone-0104281-t002-2}

  Filtering process                       Patient A   Patient B   Patient C   Patient D
  -------------------------------------- ----------- ----------- ----------- -----------
  Total variants identified                  614         564         595         580
  Exclude outside exon/splice junction       278         282         269         260
  Exclude synonymous variants                134         142         131         124
  Exclude if MAF ≥0.01                        7          12          10           3

Exon constitutes coding variants only. Splice junction constitutes +/−5 bp around an exon. A full list of variants is shown in Table S4.

Prioritisation of the variants was based on whether the genotype was consistent with disease symptoms in the family, the variant type and pathogenicity scores. For sample A with a diagnosis of RP, heterozygous mutations in *RP9*, *RP1* and *FSCN2* were deemed consistent with disease symptoms, and of these a high pathogenicity profile suggested that the strongest candidate for causation in sample A was the *RP9* variant. For sample B, though a number of changes were observed, only compound heterozygosity for a premature stop codon and a high pathogenicity missense mutation in *CRB1* fitted with the LCA diagnosis in this patient. For sample C, heterozygous variants in *RP1* and a homozygous variant in *USH2A* were considered possible candidates for causing RP in this patient. However based on pathogenicity scores and variant type, the strongest candidates for disease causation in sample C were the *RP1* variants. For sample D, only a null mutation in *PRPF31* was identified as consistent with the diagnosis of RP.

The variants that had previously been deemed causative in each sample are shown in [Table 3](#pone-0104281-t003){ref-type="table"}. As these variants had indeed been implicated as candidates for pathogenicity following filtering and prioritisation as highlighted above, without the need for segregation analysis, this confirmed that the pipeline used to identify pathogenic mutations was robust.

10.1371/journal.pone.0104281.t003

###### The previously identified pathogenic mutations in the 4 patient study.

![](pone.0104281.t003){#pone-0104281-t003-3}

  Patient    Diagnosis   Inheritance Pattern   Chr   Position      Gene     Coding Effect             cDNA change              Protein change     BLOSUM62   AGVGDclass    SIFTprediction     MAPPprediction   Zygosity
  --------- ----------- --------------------- ----- ----------- ---------- --------------- --------------------------------- ------------------- ---------- ------------ ------------------- ---------------- ----------
  A             RP              Dom.            7    33136162     *RP9*       missense           NM_203288.1:c.410A\>T           p.His137Leu      ***−3***   ***C15***    ***Deleterious***     ***bad***        Het
  B             LCA             Rec.            1    197390534    *CRB1*      nonsense          NM_201253.2:c.1576C\>T           p.Arg526\*          NA          NA              NA                 NA           Het
                                                1    197404300    *CRB1*      missense          NM_201253.2:c.3307G\>A          p.Gly1103Arg      ***−2***   ***C25***    ***Deleterious***     ***bad***        Het
  C             RP              Dom.            8    55538727     *RP1*      frameshift     NM_006269.1:c.2285_2289delTAAAT   p.Leu762Tyrfs\*17      NA          NA              NA                 NA           Het
  D             RP              Dom.           19    54621976    *PRPF31*    frameshift          NM_015629.3:c.201delT        p.Ile67Metfs\*14       NA          NA              NA                 NA           Het

The chromosome and position of the mutation is depicted according to the human genome assembly, hg19. Text in bold and italicised highlights high pathogenicity of missense variants. For BLOSUM62, high pathogenicity = \<0; AGVGD, high pathogenicity = C15 to C65; SIFT prediction, high pathogenicity = deleterious; MAPP prediction, high pathogenicity = bad. NA = not annotated.

Screening patients with unknown mutations {#s3b}
-----------------------------------------

We then selected 20 patients with various retinal degenerations for which no mutation had yet been identified and performed the pre-capture pooling procedure on the tagged DNA libraries pooled in batches of four samples. Following alignment, variant detection and filtering as described in the Methods, a list of candidate variants were identified for each sample (Table S5 in [File S1](#pone.0104281.s001){ref-type="supplementary-material"}). Candidate variants were prioritised as described previously and Sanger sequenced to confirm the presence of the mutation. Segregation was performed where DNA from other family members was available.

For MA1, family history suggested LCA with recessive inheritance caused by an autozygous mutation. The variant list following analysis of patient 2906 (a female) suggested the homozygous *CRB1* mutation (c.2832_2842+23del) as the only candidate consistent with the diagnosis in the family [@pone.0104281-Lotery1]. Analysis of the other affected case from whom DNA was available (2907) confirmed the *CRB1* mutation as the pathogenic cause of disease.

For MA2, family history of the index case (2844, a male) with unaffected parents and consanguinity suggested recessive inheritance caused by an autozygous mutation. The variant list following analysis of this case suggested a previously-identified homozygous nonsense mutation in *ABCA4* (c.6088C\>T, p.R2030\*) [@pone.0104281-Singh1] consistent with a diagnosis of CRD as the primary candidate. This mutation was indeed confirmed in the index case and subsequently found to be heterozygous in his affected offspring (2843 and 2845) suggesting that they both had an unidentified *ABCA4* mutation on their other allele which they had inherited from their mother.

For MA3, family history suggested RP with recessive inheritance due to an autozygous mutation. The variant list following analysis of patient 2908 (a female) identified a homozygous missense variant in *USH2A* (c.12874A\>G, p.N4292D) with a high pathogenicity profile as the sole candidate. The *USH2A* mutation was indeed subsequently confirmed in both affected cases from whom DNA was available.

For MA4, family history suggested recessive inheritance of RP and an autozygous mutation. The variant list following analysis of case 2833 (a male) highlighted two homozygous missense variants in *EYS* as possible candidates. Following analysis of the other affected case (2910), both *EYS* variants were homozygous and Sanger sequencing of the *EYS* terminal exon that was not covered by the capture reagent failed to identify any other changes. One of the *EYS* variants (c.7558T\>C, p.F2520L) disrupts the second laminin G subdomain which is essential for normal protein function [@pone.0104281-Khan1]. Given the degree of co-segregation and consistency with phenotype, this was considered the most likely variant to be pathogenic, but given the low pathogenicity profile scores due to the lack of amino acid conservation of the normal residue in vertebrates (data not shown), the variant was considered unproven.

For MA5 family history suggests dominant inheritance of a CRD phenotype. The variant list following analysis of patient 2278 (a female) did not highlight any obvious candidates.

For MA6, family history suggested recessive inheritance of RP with an autozygous mutation. The variant list described a previously identified homozygous missense mutation in *RDH12* (c.601T\>C, p.C201R) [@pone.0104281-Sun1] with a high pathogenicity profile which was confirmed in the case (a male) as the likely cause of disease.

For MA7, family history suggested dominant inheritance of CRD. The variant list following analysis of patient 114 (a male) highlighted the heterozygous *PROM1* mutation (c.1117C\>T, p.R373C) which was previously identified in patients with a diagnosis of cone-rod dystrophy [@pone.0104281-Yang1], [@pone.0104281-Michaelides1] as the possible cause of disease symptoms. This was confirmed by segregation in the family.

For MA8, family history suggested dominant or X-linked inheritance of RP with macular involvement. The variant list derived from analysing case 40 (a male) described a dominant variant in *NR2E3* and an X-linked variant in *RP2* as the most likely candidates. Analysis of the variants in additional family members for segregation identified that only the splicing variant in *RP2* (c.884-1G\>T) followed disease symptoms as X-linked dominant inheritance in the family.

For MA9, family history suggested dominant inheritance of a macular dystrophy phenotype. The variant list derived from analysing case 530 (a female) identified heterozygous variants in *HMCN1* and the previously reported *GUCY2D* [@pone.0104281-VanGhelue1], [@pone.0104281-Wilkie1] as the most likely candidates. Analysis of additional family members from whom DNA was available only confirmed segregation of the *GUCY2D* mutation (c.2512C\>T, p.R838C) with disease symptoms in the family.

For MA10, family history suggested recessive inheritance of CRD with an autozygous mutation. The variant list from analysing case 1857 (a male) highlighted only one candidate, a homozygous null variant in *RPGRIP1* (c.3565C\>T, p.R1189\*) that was recently reported independently as a pathogenic cause of disease [@pone.0104281-AbuSafieh1]. Segregation analysis confirmed this mutation as the cause of disease symptoms in this family.

For MA11, family history suggested recessive RP with an autozygous mutation. The variant list derived from analysing patient 2093 (a male) described a homozygous missense variant in *BBS2* (c.1895G\>C, p.R632P) as the most likely candidate. Analysis of the other affected case 1267 confirmed that the *BBS2* mutation, which was recently reported to be a common cause of RP in the Ashkenazi Jewish population [@pone.0104281-Fedick1], was the likely pathogenic cause of disease.

For MA12, family history suggested recessive CRD. The variant list derived from case 1024 (a male) highlighted two heterozygous missense variants in *CDH23* as possible candidates even though recessive mutations in this gene usually cause Usher syndrome. The absence of segregation in other family members suggested that these variants were not the pathogenic cause of disease in this family.

For MA13, family history suggested recessive inheritance of RP. Analysis of the variant list from case 863 (a female) identified missense variants in *GPR98* and *MYO7A* as the best candidates even though mutations in these genes usually cause recessive Usher syndrome. On the basis of higher pathogenicity profiles, the *GPR98* variants were analysed further. Segregation analysis confirmed that these variants were not the cause of disease symptoms in this family.

For MA14, family history suggested RP with recessive inheritance due to an autozygous mutation in each case. The variant lists for patient 1518 (a male), identified two heterozygous variants in *BBS12* and one in *FSCN2* as possible candidates though neither option appeared to fit the observed phenotype perfectly. Following analysis of the other affected sibling (1527) these variants did not segregate with the disease phenotype and so were unlikely to be the pathogenic cause of disease in this family.

For MA15, family history suggested recessive CRD with an autozygous mutation. The variant list for patient 3283 (a male) identified a previously been reported homozygous null variant in *SPATA7* (c.253C\>T, p.R85\*) [@pone.0104281-Mackay1] as the most likely candidate. Analysis of DNA from other family members highlighted that this variant segregated with the disease phenotype as expected.

For MA16 with a diagnosis of LCA, family history of the index case (3341, a male) suggested recessive inheritance and an autozygous mutation. The variant list from analysing 3340 highlighted only the previously reported LCA causing *RDH12* variant (c.506G\>A, p.R169Q) [@pone.0104281-Mackay2] as the likely cause of disease. This mutation was confirmed in the other family member.

For MA17, family history suggested recessive inheritance of RCD caused by an autozygous mutation. From the variant list of patient 3347 (a male), no obvious candidates could be identified.

For MA18, family history suggested CRD with recessive inheritance. From analysing the variant list of case 1484 (a female), compound heterozygous variants in *ABCA4* for the previously reported missense variant (c.5882G\>A, p.G1961E) [@pone.0104281-Cella1], [@pone.0104281-Burke1] as well as the heterozygous splicing variant (c.3328+1G\>C) suggested these changes as the most likely to account for the CRD in this family. This was confirmed by segregation analysis of the variants.

For MA19 family history suggested recessive inheritance of RCD with recessive inheritance with an autozygous mutation. The variant list of patient 1885 (a male), identified compound heterozygous variants in *CC2D2A* and *PCDH15* as well as a variant in *WFS1* with a high pathogenicity profile as possible candidates though none of the options appeared to fit the observed phenotype perfectly. Analysis of family members from whom DNA was available confirmed three of the putative variants were artefacts and the remaining ones in *CC2D2A* and *WFS1* did not segregate with disease.

For MA20, family history suggested RP with recessive inheritance due to an autozygous mutation. The variant list of case 472 (a male) identified a single homozygous missense variant in *TRPM1* as well as compound heterozygous variants in *CEP290* and a variant in *CA4*, though none of these candidates appeared to exactly fit the observed phenotype. As suspected, these variants were either artefacts or failed to segregate with disease in this family suggesting that the pathogenic cause of disease has yet to be identified.

Using this approach likely pathogenic mutation(s) were identified in 12 out of 20 cases (60%). A list of these mutations is highlighted in [Table 4](#pone-0104281-t004){ref-type="table"} and the sequence chromatograms of each candidate variant highlighted in Figure S1 in [File S1](#pone.0104281.s001){ref-type="supplementary-material"}. To summarise, the mutations consisted of previously reported mutations of clinical significance in *ABCA4* (c.6088C\>T, p.R2030\* [@pone.0104281-Singh1] and c.5882G\>A, p.G1961E [@pone.0104281-Cella1], [@pone.0104281-Burke1]), *RDH12* (c.601T\>C, p.C201R [@pone.0104281-Sun1] and c.506G\>A, p.R169Q [@pone.0104281-Mackay2]), *PROM1* (c.1117C\>T, p.R373C [@pone.0104281-Yang1], [@pone.0104281-Michaelides1]), *GUCY2D* (c.2512C\>T, p.R838C [@pone.0104281-VanGhelue1], [@pone.0104281-Wilkie1]), *RPGRIP1* (c.3565C\>T, p.R1189\* [@pone.0104281-AbuSafieh1]), *BBS2* (c.1895G\>C, p.R632P [@pone.0104281-Fedick1]) and *SPATA7* (c.253C\>T, p.R85\* [@pone.0104281-Mackay1]) and new mutations in *CRB1* (c.2832_2842+23del), *USH2A* (c.12874A\>G, p.N4292D), *RP2* (c.884-1G\>T) and *ABCA4* (c.3328+1G\>C). Of the 8 cases for which the pathogenic mutation could not be identified, the absence of zero-coverage targeted regions suggested that a homozygous deletion removing an exon(s) was not the cause of disease in these patients.

10.1371/journal.pone.0104281.t004

###### List of confirmed likely pathogenic mutations in the 20 patient study.

![](pone.0104281.t004){#pone-0104281-t004-4}

  ID           Diagnosis        Inheritance Pattern        Chr         Position      Gene      Coding Effect            cDNA change            Protein change   BLOSUM62   AGVGD class    SIFT prediction    MAPP prediction   Zygosity                      \[Reference\]
  ------ --------------------- --------------------- ---------------- ----------- ----------- --------------- ------------------------------- ---------------- ---------- ------------- ------------------- ----------------- ---------- -----------------------------------------------------
  MA1             LCA                  Rec.                 1          197398744    *CRB1*      frameshift     NM_201253.2:c.2832_2842+23del        p.?            NA          NA               NA                 NA            Homo    
  MA2             CRD                Rec./Dom.              1          94471056     *ABCA4*      nonsense         NM_000350.2:c.6088C\>T        p.Arg2030\*        NA          NA               NA                 NA            Homo                   [@pone.0104281-Singh1]
  MA3             RP                   Rec.                 1          215848379    *USH2A*      missense         NM_206933.2:c.12874A\>G       p.Asn4292Asp       1        ***C15***    ***Deleterious***      ***bad***        Homo    
  MA4             RP                   Rec.           None confirmed                                                                                                                                                                     
  MA5             CRD                  Dom.           None confirmed                                                                                                                                                                     
  MA6             RP                   Rec.                 14         68193850     *RDH12*      missense          NM_152443.2:c.601T\>C        p.Cys201Arg     ***−3***       C0        ***Deleterious***      ***bad***        Homo                    [@pone.0104281-Sun1]
  MA7             CRD                  Dom.                 4          16014922     *PROM1*      missense         NM_006017.2:c.1117C\>T        p.Arg373Cys     ***−3***       C0        ***Deleterious***      ***bad***        Het      [@pone.0104281-Yang1], [@pone.0104281-Michaelides1]
  MA8     RP with maculopathy      Dom./X-link.             X          46736939      *RP2*       splicing         NM_006915.2:c.884-1G\>T           p.?            NA          NA               NA                 NA            Homo    
  MA9             MD                   Dom.                 17          7918018    *GUCY2D*      missense         NM_000180.3:c.2512C\>T        p.Arg838Cys     ***−3***    ***C65***    ***Deleterious***      ***bad***        Het      [@pone.0104281-VanGhelue1], [@pone.0104281-Wilkie1]
  MA10            CRD                  Rec.                 14         21813304    *RPGRIP1*     nonsense         NM_020366.3:c.3565C\>T        p.Arg1189\*        NA          NA               NA                 NA            Homo                 [@pone.0104281-AbuSafieh1]
  MA11            RP                   Rec.                 16         56530894     *BBS2*       missense         NM_031885.3:c.1895G\>C        p.Arg632Pro     ***−2***    ***C15***        Tolerated          ***bad***        Homo                   [@pone.0104281-Fedick1]
  MA12            CRD                  Rec.           None confirmed                                                                                                                                                                     
  MA13            RP                   Rec.           None confirmed                                                                                                                                                                     
  MA14            RP                   Rec.           None confirmed                                                                                                                                                                     
  MA15            CRD                  Rec.                 14         88883069    *SPATA7*      nonsense          NM_018418.4:c.253C\>T         p.Arg85\*         NA          NA               NA                 NA            Homo                   [@pone.0104281-Mackay1]
  MA16            LCA                  Rec.                 14         68193755     *RDH12*      missense          NM_152443.2:c.506G\>A        p.Arg169Gln        1        ***C35***    ***Deleterious***      ***bad***        Homo                   [@pone.0104281-Mackay2]
  MA17            RCD                  Rec.           None confirmed                                                                                                                                                                     
  MA18            CRD                  Rec.                 1          94508316     *ABCA4*      splicing        NM_000350.2:c.3328+1G\>C           p.?            NA          NA               NA                 NA            Het     
                                                                       94473807     *ABCA4*      missense         NM_000350.2:c.5882G\>A        p.Gly1961Glu    ***−2***    ***C65***    ***Deleterious***      ***bad***        Het        [@pone.0104281-Cella1], [@pone.0104281-Burke1]
  MA19            RCD                  Rec.           None confirmed                                                                                                                                                                     
  MA20            RP                   Rec.           None confirmed                                                                                                                                                                     

The ID and diagnosis of the cases studied as well as the chromosome and position of the mutation according to the human genome assembly hg19, gene, coding effect, cDNA and protein nomenclature, BLOSUM62, AGVGD class, SIFT prediction, MAPP prediction, zygosity and whether the mutation has been previously implicated into causing disease are shown. Text in bold and italicised highlights high pathogenicity prediction for missense variants. For BLOSUM62, high pathogenicity = \<0; AGVGD, high pathogenicity = C15 to C65; SIFT prediction, high pathogenicity = deleterious; MAPP prediction, high pathogenicity = bad. NA = not annotated. Homo = homozygous. Het = heterozygous.

Discussion {#s4}
==========

In this paper we describe a previously published strategy for target capture and next generation sequencing that utilises tagging and pooling of DNAs in batches of four prior to enrichment [@pone.0104281-Harakalova1]. This approach refines the use of targeted capture technology, facilitating the enrichment of exons from pooled samples using a single aliquot of capture reagent. This strategy differs from previously described methods which usually pool samples after the hybridization step to multiplex onto one lane of the sequencer. The technology described herein will contribute to the development of a retinal dystrophy diagnostic screening service by reducing costs associated with using a single capture reagent to analyse up to four samples in a single experiment. We also describe use of a reagent designed to enrich patient genomic DNA for all retinal dystrophy genes that were listed in Retnet as of July 2010. A recent update in January 2014 has 66 additional genes found to have mutations causing retinal dystrophy that were not included in the reagent used in this study. The flexibility of our approach means that these genes can be incorporated into subsequent versions of the targeted reagent. A methodological drawback of the targeted hybridisation approach is that regions containing repeat sequences cannot be adequately covered due to binding of the target DNA to multiple sites of repetitive sequence. In the current reagent, 9 exons including the *RPGR* ORF15 could not be covered because of repeat sequence, suggesting that these exons will have to be sequenced using alternative methods. In terms of data analysis, we observed a number of sequencing artefacts that may be due to low coverage, low sequence quality or the pooling of DNA samples but the most likely source was due to variant calling. In order to reduce the number of false negative results the stringency of variant calling algorithm was relaxed. This encompassing approach to capture all possible variants inevitably meant that there were also a number of false positives in the annotated variant lists.

The use of next generation sequencing for retinal disease diagnosis has been previously described (see [Table 5](#pone-0104281-t005){ref-type="table"}). Researchers have used different target enrichment methods such as solid phase capture arrays [@pone.0104281-Simpson1], [@pone.0104281-Neveling1], [@pone.0104281-Shanks1] or PCR amplicons based approaches [@pone.0104281-Bowne1], [@pone.0104281-Coppieters1] as opposed to liquid phase capture [@pone.0104281-Audo1], [@pone.0104281-OSullivan1] and have run the libraries on different machines such as the Roche 454 [@pone.0104281-Bowne1], [@pone.0104281-Neveling1], [@pone.0104281-Shanks1] or the ABI SOLiD [@pone.0104281-OSullivan1] rather than the Illumina Genome Analyser [@pone.0104281-Bowne1]--[@pone.0104281-Coppieters1]. Success in identifying the pathogenic mutation has, to date varied from 18% (3 out of 17 cases studied) [@pone.0104281-Coppieters1] to 60% (3 out of 5 cases studied) [@pone.0104281-Simpson1] and there does not appear to be any correlation between successfully identifying the pathogenic mutation and the library preparation method or machine used for the study. The approach described in this paper gave a 60% (12 out of 20 cases studied) success rate, which is higher than the majority of previous studies. One possible reason for this may be that we focussed on studying families with multiple affected members rather than single cases with no family history. This allowed us to assess the pathogenicity of candidate disease causing variants by following the transmission of the mutation with the disease phenotype. It is interesting to note when studying isolated cases that several examples of *de novo* mutations as the cause of disease have been demonstrated [@pone.0104281-Neveling1], [@pone.0104281-Shanks1]. Another possible reason for the increased detection rate in this study is the high number of consanguineous cases in the local Yorkshire population, which allows filtering on the basis of homozygosity.

10.1371/journal.pone.0104281.t005

###### Comparison of the methodological approaches in recent publications that have used high throughput next generation sequencing for retinal disease diagnosis.

![](pone.0104281.t005){#pone-0104281-t005-5}

  Authors \[Reference\]                           Detecting phenotypes     Library preparation                       NGS instrument                         Number of independent samples tested        Pathogenic mutation identified (%)  
  ---------------------------------------------- ---------------------- ------------------------- ---------------------------------------------------- ----------------------------------------------- ------------------------------------ ----------
  Bowne et al [@pone.0104281-Bowne1]                      adRP                     46                                PCR amplicons                      454GS FLX Titanium (Roche) & GAIIx (Illumina)                   21                   5 (24%)
  Simpson et al [@pone.0104281-Simpson1]                   RP                      45               Solid phase customised capture array (NimbleGen)                  GAIIx (Illumina)                                  5                    3 (60%)
  Coppieters et al [@pone.0104281-Coppieters1]            LCA                      16                                PCR amplicons                                    GAIIx (Illumina)                                  17                   3 (18%)
  Neveling et al [@pone.0104281-Neveling1]                 RP                      111              Solid phase customised capture array (NimbleGen)             454GS FLX Titanium (Roche)                            100                   36 (36%)
  Audo et al [@pone.0104281-Audo1]                         RD                      254             Liquid phase targeted SureSelect capture (Agilent)                 GAIIx (Illumina)                                  13                   7 (54%)
  O\'Sullivan et al [@pone.0104281-OSullivan1]             RD                      105             Liquid phase targeted SureSelect capture (Agilent)            SOLiD 4 (Life Technologies)                            50                   21 (42%)
  Shanks et al [@pone.0104281-Shanks1]                  RP & CRD                   73               Solid phase customised capture array (NimbleGen)             454GS FLX Titanium (Roche)                             36                   9 (25%)
  Watson et al \[This paper\]                              RD            162 (Retnet, July 2010)   Liquid phase targeted SureSelect capture (Agilent)                 GAIIx (Illumina)                                  20                   12 (60%)

adRP = autosomal dominant retinitis pigmentosa; CRD = cone rod dystrophy; LCA = leber congenital amaurosis;

RD = retinal dystrophies; RP = retinitis pigmentosa.

Patient feedback has highlighted the need for, and perceived value of, a definitive diagnosis based on genetic testing, and has shown that patients are motivated by a variety of factors to seek genetic testing [@pone.0104281-Willis1]. Individuals may see many different eye specialists before a definitive diagnosis is made, whereas genetic testing can rapidly provide an accurate diagnosis. Furthermore, a genetic diagnosis can confirm the way in which the condition is inherited, giving clearer estimates of risk for patients and their relatives thus informing family planning decisions. Genetic testing can also facilitate pre-implantation diagnosis or prenatal testing as well as carrier testing in those who wish to know. In some cases such information may lead to improvements in therapy or direct patients towards trials for new potential therapies. It can also provide patients with an accurate guide to future function. Using this information, individuals can make informed decisions regarding education, employment and lifestyle.

To conclude, we report here that tagging DNA and pooling samples prior to hybridisation capture and next generation sequencing is a viable high throughput method for the genetic diagnosis of retinal dystrophies. This approach leaves a residual cohort of patients and families with retinal dystrophy that could not be resolved using the methods described. Their mutations may be in the known genes within regions that were not targeted such as the regulatory or intronic regions or one of the 9 exons of repetitive sequence. Alternatively, the mutation may be a cryptic splice site created by one of the synonymous variants that were removed during filtering. On the other hand, the mutation may be in one of the 66 additional genes that have been added to RetNet since the capturing reagent was manufactured, or it may be in a new gene that has never been implicated in retinal dystrophy. Nevertheless, this cohort serves as a powerful resource for further gene and mutation discovery by whole exome as well as genome sequencing.

Supporting Information {#s5}
======================

###### 

**Supplementary figure and tables.**

(PDF)

###### 

Click here for additional data file.

We would like to thank the patients and their families who participated in this study.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: CMW DAP ES RC CAJ GT CT CFI MA. Performed the experiments: CMW ME-A DAP JEM CVL. Analyzed the data: CMW ME-A DAP IMC. Contributed reagents/materials/analysis tools: MM. Wrote the paper: CMW CFI MA.
